The U.S. Food and Drug Administration (FDA) has released a new draft guidance, “Forms FDA 3542a and FDA 3542: Questions and Answers,” intended to help New Drug Application (NDA) applicants and holders correctly submit patent information and reduce common filing errors.
The guidance addresses frequently asked questions and is organized into three key areas:
- Obtaining and completing Forms FDA 3542a and FDA 3542
- Section 6 of the forms, titled “Declaration Certification”
- Submitting patent information to FDA
Understanding Which Form to Use
The required form depends on the status of the NDA.
Form FDA 3542a
Form FDA 3542a is used by NDA applicants when submitting patent information related to an unapproved original NDA, amendment, or supplement. The form applies to patents claiming:
- Drug substances (active ingredients)
- Drug products (formulations and compositions)
- Proposed methods of use
Form FDA 3542
Form FDA 3542 is used by NDA holders when submitting patent information associated with an approved NDA or supplement. It applies to patents claiming:
- Approved drug substances
- Approved drug products
- Approved methods of use
These requirements are established under 21 CFR 314.53(c) and (d).
Why FDA Issued the Guidance
According to FDA, the draft guidance is intended to minimize applicant confusion, reduce submission errors, and improve the accuracy and consistency of patent information listed in the Orange Book. More complete and timely submissions can help streamline the review process for both NDA and Abbreviated New Drug Application (ANDA) applicants.
The effort supports FDA’s Drug Competition Action Plan, which seeks to improve the efficiency of generic drug development, review, and approval.
FDA also noted that comments on the draft guidance may address the applicability of Executive Order 14192 and OMB Memorandum M-25-20, including any associated costs or savings that could result from the guidance.
What This Means for Industry
Pharmaceutical manufacturers and NDA holders should review their internal procedures for submitting patent information to ensure the appropriate form is used. Clarifying the requirements surrounding Forms FDA 3542a and 3542 can help avoid unnecessary delays, reduce follow-up questions from FDA, and improve the overall efficiency of the submission process.
ASK Alba™
Answers • Solutions • Knowledge
Keeping up with FDA regulatory developments can help companies avoid costly delays and maintain compliance throughout the product lifecycle. Alba helps clients stay informed about changes affecting international trade and regulated industries.
Questions? Contact us:
https://albawheelsup.com/contact-us/
Reference
FDA Draft Guidance: “Forms FDA 3542a and FDA 3542: Questions and Answers”
